1
|
Hussain F, Rahman FI, Saha P, Mikami A, Osawa T, Obika S, Rahman SMA. Synthesis of Sugar and Nucleoside Analogs and Evaluation of Their Anticancer and Analgesic Potentials. Molecules 2022; 27:molecules27113499. [PMID: 35684435 PMCID: PMC9182362 DOI: 10.3390/molecules27113499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 05/21/2022] [Accepted: 05/22/2022] [Indexed: 02/04/2023] Open
Abstract
Chemical modification of sugars and nucleosides has a long history of producing compounds with improved selectivity and efficacy. In this study, several modified sugars (2–3) and ribonucleoside analogs (4–8) have been synthesized from α-d-glucose in a total of 21 steps. The compounds were tested for peripheral anti-nociceptive characteristics in the acetic acid-induced writhing assay in mice, where compounds 2, 7, and 8 showed a significant reduction in the number of writhes by 56%, 62%, and 63%, respectively. The compounds were also tested for their cytotoxic potential against human HeLa cell line via trypan blue dye exclusion test followed by cell counting kit-8 (CCK-8) assay. Compound 6 demonstrated significant cytotoxic activity with an IC50 value of 54 µg/mL. Molecular docking simulations revealed that compounds 2, 7, and 8 had a comparable binding affinity to cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. Additionally, the bridged nucleoside analogs 7 and 8 potently inhibited adenosine kinase enzyme as well, which indicates an alternate mechanistic pathway behind their anti-nociceptive action. Cytotoxic compound 6 demonstrated strong docking with cancer drug targets human cytidine deaminase, proto-oncogene tyrosine-protein kinase Src, human thymidine kinase 1, human thymidylate synthase, and human adenosine deaminase 2. This is the first ever reporting of the synthesis and analgesic property of compound 8 and the cytotoxic potential of compound 6.
Collapse
Affiliation(s)
- Fahad Hussain
- Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh; (F.H.); (F.I.R.); (P.S.)
| | - Fahad Imtiaz Rahman
- Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh; (F.H.); (F.I.R.); (P.S.)
| | - Poushali Saha
- Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh; (F.H.); (F.I.R.); (P.S.)
| | - Atsushi Mikami
- Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Osaka 565-0871, Japan; (A.M.); (T.O.); (S.O.)
| | - Takashi Osawa
- Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Osaka 565-0871, Japan; (A.M.); (T.O.); (S.O.)
| | - Satoshi Obika
- Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Osaka 565-0871, Japan; (A.M.); (T.O.); (S.O.)
| | - S. M. Abdur Rahman
- Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh; (F.H.); (F.I.R.); (P.S.)
- Correspondence: ; Tel.: +880-1732477343
| |
Collapse
|
2
|
Bagheri S, Saboury AA, Haertlé T. Adenosine deaminase inhibition. Int J Biol Macromol 2019; 141:1246-1257. [PMID: 31520704 DOI: 10.1016/j.ijbiomac.2019.09.078] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Revised: 09/09/2019] [Accepted: 09/10/2019] [Indexed: 12/18/2022]
Abstract
Adenosine deaminase is a critical enzyme in purine metabolism that regulates intra and extracellular adenosine concentrations by converting it to inosine. Adenosine is an important purine that regulates numerous physiological functions by interacting with its receptors. Adenosine and consequently adenosine deaminase can have pro or anti-inflammatory effects on tissues depending on how much time has passed from the start of the injury. In addition, an increase in adenosine deaminase activity has been reported for various diseases and the significant effect of deaminase inhibition on the clinical course of different diseases has been reported. However, the use of inhibitors is limited to only a few medical indications. Data on the increase of adenosine deaminase activity in different diseases and the impact of its inhibition in various cases have been collected and are discussed in this review. Overall, the evidence shows that many studies have been done to introduce inhibitors, however, in vivo studies have been much less than in vitro, and often have not been expanded for clinical use.
Collapse
Affiliation(s)
- S Bagheri
- Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
| | - A A Saboury
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
| | - T Haertlé
- Institut National de la Recherche Agronomique, Nantes, France
| |
Collapse
|
3
|
Abstract
This review reports the chemistry of 1,2,4-triazepines. Heterocyclic 1,2,4-triazepines are mono and fused cycles.
Collapse
Affiliation(s)
- Khaled M. Elattar
- Chemistry Department
- Faculty of Science
- Mansoura University
- Mansoura
- Egypt
| | | | - Ibrahim A. Mousa
- Chemistry Department
- Faculty of Science
- South Valley University
- Egypt
| | - Ahmed El-Mekabaty
- Chemistry Department
- Faculty of Science
- Mansoura University
- Mansoura
- Egypt
| |
Collapse
|
4
|
A comprehensive review on bioactive fused heterocycles as purine-utilizing enzymes inhibitors. Med Chem Res 2014. [DOI: 10.1007/s00044-014-1295-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
5
|
Hassan AA, Bebair TM, El-Gamal MI. Synthesis of Pyrazolylthiazole and Pyrazolyl-1,2,4-Triazepine Derivatives. JOURNAL OF CHEMICAL RESEARCH 2014. [DOI: 10.3184/174751914x13862607015688] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In a multistep reaction, ( Z)-methyl 2-[( Z)-2-hydrazono-4-oxo-]-(3-substituted-1 H-pyrazol-5-yl)thiazolidin-5-ylidine)acetate, ( Z)-methyl-1-(2-methoxy-2-oxoethyl)-2-[( Z)-5-(2-methoxy-2-oxoethylidene)-4-oxo-3-(3-substituted-1 H-pyrazol-5-yl)-thiazolidin-2-ylidine)hydrazinecarboxylates and methyl 5-oxo-4-(3-substituted-1 H-pyrazol-5-yl)-3-thioxo-3,4,5,6-tetrahydro-2 H-1,2,4-triazepine-7-carboxylates have been formed in good yield from the reaction of N-(3-substituted-1 H-pyrazol-5-yl)-hydrazinecarbothioamides with dimethyl acetylenedicarboxylate. Explanations of these conversions involving nucleophilic reactions and condensations are presented.
Collapse
Affiliation(s)
- Alaa A. Hassan
- Chemistry Department, Faculty of Science, Minia University, 61519 El-Minia, Egypt
| | - Tarek M. Bebair
- Chemistry Department, Faculty of Science, Minia University, 61519 El-Minia, Egypt
- Department of Biomolecular Science, University of Science and Technology, 113 Gwahangno, Yuseong-gu, Daejeon 305-333, Korea
| | - Mohammed I. El-Gamal
- Department of Biomolecular Science, University of Science and Technology, 113 Gwahangno, Yuseong-gu, Daejeon 305-333, Korea
- Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura 35516, Egypt
| |
Collapse
|
6
|
Reaction of acetylenedicarboxylic acids esters with 4,5-dihydro-1H-pyrazole-1-carbothioamides and 3,4,5,6-tetrahydro-2H-1,2,4-triazepine-3-thiones. Chem Heterocycl Compd (N Y) 2011. [DOI: 10.1007/s10593-011-0850-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Gillerman I, Fischer B. Investigations into the origin of the molecular recognition of several adenosine deaminase inhibitors. J Med Chem 2010; 54:107-21. [PMID: 21138280 DOI: 10.1021/jm101286g] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Inhibitors of adenosine deaminase (ADA, EC 3.5.4.4) are potential therapeutic agents for the treatment of various health disorders. Several highly potent inhibitors were previously identified, yet they exhibit unacceptable toxicities. We performed a SAR study involving a series of C2 or C8 substituted purine-riboside analogues with a view to discover less potent inhibitors with a lesser toxicity. We found that any substitution at C8 position of nebularine resulted in total loss of activity toward calf intestinal ADA. However, several 2-substituted-adenosine, 8-aza-adenosine, and nebularine analogues exhibited inhibitory activity. Specifically, 2-Cl-purine riboside, 8-aza-2-thiohexyl adenosine, 2-thiohexyl adenosine, and 2-MeS-purine riboside were found to be competitive inhibitors of ADA with K(i) values of 25, 22, 6, and 3 μM, respectively. We concluded that electronic parameters are not major recognition determinants of ADA but rather steric parameters. A C2 substituent which fits ADA hydrophobic pocket and improves H-bonding with the enzyme makes a good inhibitor. In addition, a gg rotamer about C4'-C5' bond is apparently an important recognition determinant.
Collapse
Affiliation(s)
- Irina Gillerman
- Department of Chemistry, Gonda-Goldschmied Medical Research Center, Bar-Ilan University, Ramat-Gan, Israel
| | | |
Collapse
|
8
|
Ujjinamatada RK, Phatak P, Burger AM, Hosmane RS. Inhibition of Adenosine Deaminase by Analogues of Adenosine and Inosine, Incorporating a Common Heterocyclic Base, 4(7)-Amino-6(5)H-imidazo[4,5-d]pyridazin-7(4)one. J Med Chem 2008; 51:694-8. [DOI: 10.1021/jm700931t] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Ravi K. Ujjinamatada
- Laboratory for Drug Design and Synthesis, Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250, and Marlene and Stewart Greenbaum Cancer Center, Experimental Therapeutics Program, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, Maryland 21201
| | - Pornima Phatak
- Laboratory for Drug Design and Synthesis, Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250, and Marlene and Stewart Greenbaum Cancer Center, Experimental Therapeutics Program, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, Maryland 21201
| | - Angelika M. Burger
- Laboratory for Drug Design and Synthesis, Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250, and Marlene and Stewart Greenbaum Cancer Center, Experimental Therapeutics Program, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, Maryland 21201
| | - Ramachandra S. Hosmane
- Laboratory for Drug Design and Synthesis, Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250, and Marlene and Stewart Greenbaum Cancer Center, Experimental Therapeutics Program, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, Maryland 21201
| |
Collapse
|